ALNY – Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.ALNY
$322.92Name : Alnylam Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $42,104,893,440.00
EPSttm : -2.1
Alnylam Pharmaceuticals, Inc.
$322.92
0.03%$0.09Float Short %
2.71
Margin Of Safety %
Put/Call OI Ratio
1.07
EPS Next Q Diff
0.85
EPS Last/This Y
3.21
EPS This/Next Y
3.13
Price
323.04
Target Price
330.75
Analyst Recom
1.79
Performance Q
19.12
Relative Volume
2.09
Beta
0.21
Ticker: ALNY
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | ALNY | 305.5 | 0.74 | 1.22 | 14655 |
| 2025-06-03 | ALNY | 303.68 | 0.75 | 0.62 | 14700 |
| 2025-06-04 | ALNY | 305.15 | 0.75 | 0.46 | 15053 |
| 2025-06-05 | ALNY | 307.87 | 0.75 | 0.93 | 15079 |
| 2025-06-06 | ALNY | 300.89 | 0.75 | 0.85 | 15074 |
| 2025-06-09 | ALNY | 303.86 | 0.75 | 0.09 | 15132 |
| 2025-06-10 | ALNY | 302.24 | 0.75 | 2.07 | 15182 |
| 2025-06-11 | ALNY | 298.46 | 0.76 | 0.15 | 15196 |
| 2025-06-12 | ALNY | 304.7 | 0.76 | 1.06 | 15215 |
| 2025-06-13 | ALNY | 308 | 0.76 | 0.69 | 15255 |
| 2025-06-16 | ALNY | 309.05 | 0.76 | 5.11 | 15272 |
| 2025-06-17 | ALNY | 308.74 | 0.77 | 1.73 | 15410 |
| 2025-06-18 | ALNY | 312.37 | 0.77 | 0.44 | 15462 |
| 2025-06-20 | ALNY | 309.82 | 0.79 | 0.22 | 16187 |
| 2025-06-23 | ALNY | 313.25 | 0.93 | 0.45 | 11016 |
| 2025-06-24 | ALNY | 324.69 | 0.93 | 2.75 | 11075 |
| 2025-06-25 | ALNY | 321.89 | 1.02 | 0.25 | 12063 |
| 2025-06-26 | ALNY | 318.15 | 1.02 | 5.95 | 12134 |
| 2025-06-27 | ALNY | 323.03 | 1.07 | 0.41 | 12441 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | ALNY | 306.18 | -122.0 | 271.1 | 0.92 |
| 2025-06-03 | ALNY | 303.77 | -122.0 | 270.3 | 0.92 |
| 2025-06-04 | ALNY | 305.26 | -122.0 | 271.1 | 0.92 |
| 2025-06-05 | ALNY | 308.00 | -119.4 | 271.3 | 0.93 |
| 2025-06-06 | ALNY | 300.76 | -119.4 | 269.3 | 0.93 |
| 2025-06-09 | ALNY | 304.00 | -119.4 | 271.4 | 0.93 |
| 2025-06-10 | ALNY | 302.31 | -119.4 | 270.4 | 0.93 |
| 2025-06-11 | ALNY | 298.62 | -119.4 | 270.0 | 0.93 |
| 2025-06-12 | ALNY | 304.67 | -119.4 | 272.1 | 0.93 |
| 2025-06-13 | ALNY | 307.92 | -118.3 | 271.4 | 0.94 |
| 2025-06-16 | ALNY | 308.90 | -118.3 | 271.0 | 0.94 |
| 2025-06-17 | ALNY | 308.75 | -118.3 | 270.7 | 0.94 |
| 2025-06-18 | ALNY | 312.32 | -118.3 | 271.5 | 0.94 |
| 2025-06-20 | ALNY | 309.70 | -118.3 | 270.3 | 0.94 |
| 2025-06-23 | ALNY | 313.13 | -118.3 | 277.3 | 0.94 |
| 2025-06-24 | ALNY | 325.00 | -118.3 | 279.2 | 0.94 |
| 2025-06-25 | ALNY | 322.03 | -118.3 | 276.0 | 0.94 |
| 2025-06-26 | ALNY | 318.27 | -118.3 | 275.8 | 0.94 |
| 2025-06-27 | ALNY | 323.04 | -109.5 | 277.6 | 1.03 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | ALNY | -2.02 | 1.50 | 2.95 |
| 2025-06-03 | ALNY | -2.87 | 1.50 | 2.95 |
| 2025-06-04 | ALNY | -2.87 | 1.50 | 2.95 |
| 2025-06-05 | ALNY | -2.87 | 1.50 | 2.95 |
| 2025-06-06 | ALNY | -2.87 | 1.50 | 2.95 |
| 2025-06-09 | ALNY | -2.87 | 1.50 | 2.95 |
| 2025-06-10 | ALNY | -2.87 | 1.50 | 2.95 |
| 2025-06-11 | ALNY | -2.87 | 1.50 | 2.77 |
| 2025-06-12 | ALNY | -2.87 | 1.50 | 2.77 |
| 2025-06-13 | ALNY | -2.87 | 1.50 | 2.77 |
| 2025-06-16 | ALNY | -2.84 | 1.62 | 2.77 |
| 2025-06-18 | ALNY | -2.84 | 1.62 | 2.77 |
| 2025-06-20 | ALNY | -2.84 | 1.62 | 2.77 |
| 2025-06-23 | ALNY | -2.84 | 1.51 | 2.77 |
| 2025-06-24 | ALNY | -2.84 | 1.51 | 2.77 |
| 2025-06-25 | ALNY | -2.84 | 1.51 | 2.77 |
| 2025-06-26 | ALNY | -2.84 | 1.51 | 2.71 |
| 2025-06-27 | ALNY | -2.84 | 1.51 | 2.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.44
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
0.41
Insider Transactions
-2.84
Institutional Transactions
1.51
Beta
0.21
Average Sales Estimate Current Quarter
636
Average Sales Estimate Next Quarter
725
Fair Value
Quality Score
45
Growth Score
54
Sentiment Score
98
Actual DrawDown %
0.9
Max Drawdown 5-Year %
-42.5
Target Price
330.75
P/E
Forward P/E
169.18
PEG
P/S
17.93
P/B
364.43
P/Free Cash Flow
EPS
-2.09
Average EPS Est. Cur. Y
1.03
EPS Next Y. (Est.)
4.16
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-11.49
Relative Volume
2.09
Return on Equity vs Sector %
-257.5
Return on Equity vs Industry %
-239.7
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.12
EBIT Estimation
277.6
Alnylam Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 2230
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
stock quote shares ALNY – Alnylam Pharmaceuticals, Inc. Stock Price stock today
news today ALNY – Alnylam Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALNY – Alnylam Pharmaceuticals, Inc. yahoo finance google finance
stock history ALNY – Alnylam Pharmaceuticals, Inc. invest stock market
stock prices ALNY premarket after hours
ticker ALNY fair value insiders trading